Abstract

You have accessJournal of UrologyKidney Cancer: Basic Research III1 Apr 2012444 ABERRANT EXPRESSION OF C5AR IN METASTATIC RENAL CELL CARCINOMA Yoshihiro Maeda, Yoshihiro Wada, Yoshiaki Kawano, Ken Kikuchi, Wataru Takahashi, Jiro Honda, Juro Nakanishi, Takahisa Imamura, and Masatoshi Eto Yoshihiro MaedaYoshihiro Maeda Kumamoto, Japan More articles by this author , Yoshihiro WadaYoshihiro Wada Kumamoto, Japan More articles by this author , Yoshiaki KawanoYoshiaki Kawano Kumamoto, Japan More articles by this author , Ken KikuchiKen Kikuchi Kumamoto, Japan More articles by this author , Wataru TakahashiWataru Takahashi Kumamoto, Japan More articles by this author , Jiro HondaJiro Honda Kumamoto, Japan More articles by this author , Juro NakanishiJuro Nakanishi Kumamoto, Japan More articles by this author , Takahisa ImamuraTakahisa Imamura Kumamoto, Japan More articles by this author , and Masatoshi EtoMasatoshi Eto Kumamoto, Japan More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.02.511AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Anaphylatoxin C5a is a-fragment of complement 5th component, which is a potent chemoattractant. Recent studies showed C5a receptor (C5aR) is aberrantly expressed in human cancers, which plays a crucial role in cancer invasion via enhancing cancer cell motility. In this study, we analysed expression of C5aR in metastatic and non-metastatic renal cell carcinoma (RCC). The possible role of C5aR in renal cancer cells was also investigated by in vitro analysis. METHODS We retrospectively analysed data from 127 Renal Cell Carcinoma patients who had received radical or partial nephrectomy or biopsy between 2002 and 2011. C5aR expression in renal cell carcinoma samples were analysed by immunohistochemistry using Formalin-Fixed Paraffin-Embedded tissue samples, and correlation of C5aR staining and clinicopathological parameters was analysed. For in vitro analysis, 293 cells, which are derived from human renal epithelial cells, were transiently transfected with C5aR expression plasmid then cell lysate was subjected to immunoblotting with anti-total or phospho ERK antibodies. RESULTS This study used data from 127 RCC patients (86 men and 41 women). The median (range) age of the patients was 62 (22-87) years. 97 patients (66 men and 31 women) had non-metastatic RCC, whose median (range) age was 63 (22-85) years, and 30 patients (20 men and 10 women) had metastatic RCC (mRCC), whose median (range) age was 59 (30-87) years. Immunohistochemical analysis showed that 96.7% of mRCC was C5aR positive, whereas 50.5% of non-metastatic RCC expressed C5aR (Fisher&undefined;fs Exact Test, p<0.001). There is no correlation between C5aR expression and other clinicopathological parameters (e.g. stage, Fuhrman grade, histological subtypes). In vitro experiment revealed that overexpression of C5aR triggers activation of ERK in renal epithelium-derived cells, which is a crucial molecular event for renal cell carcinoma progression. CONCLUSIONS This study suggests that aberrant expression of C5aR may be a pivotal step for cancer cell metastasis. © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 187Issue 4SApril 2012Page: e182 Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.MetricsAuthor Information Yoshihiro Maeda Kumamoto, Japan More articles by this author Yoshihiro Wada Kumamoto, Japan More articles by this author Yoshiaki Kawano Kumamoto, Japan More articles by this author Ken Kikuchi Kumamoto, Japan More articles by this author Wataru Takahashi Kumamoto, Japan More articles by this author Jiro Honda Kumamoto, Japan More articles by this author Juro Nakanishi Kumamoto, Japan More articles by this author Takahisa Imamura Kumamoto, Japan More articles by this author Masatoshi Eto Kumamoto, Japan More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.